Peter Kochupura, MD
Pulmonary Disease · Morgantown, WVNPI 1184813388
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Johnson & Johnson at 55.3% of the total. Reporting peaked in 2023 at $6,682 and has fallen 66.7% since, to $2,222 in 2025. Among pulmonary disease clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 86 payments — averaging $257.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$12K
- Intuitive Surgical$7K
- Medical Device Business Services, Inc.$2K
- Pulmonx Corporation$171
- AstraZeneca$150
- Regeneron Healthcare Solutions, Inc.$135
- plus $253 from 6 others
What the payments were for
- Consulting fees$11,90054%
- Travel & lodging$3,04914%
- Food & beverage$4,71521%
- Education$2,50011%
- Gifts$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 37 | $12,268 |
| Intuitive Surgical | 28 | $6,752 |
| Medical Device Business Services, Inc. | 1 | $2,450 |
| Pulmonx Corporation | 1 | $171 |
| AstraZeneca | 9 | $150 |
| Regeneron Healthcare Solutions, Inc. | 1 | $135 |
| Verona Pharma, Inc. | 2 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $58 |
| Galvanize Therapeutics, Inc | 1 | $51 |
| Sanofi | 2 | $47 |
| Amgen | 1 | $22 |
| Boehringer Ingelheim | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,180 in reported general payments places this provider in the 90th percentile of 89 pulmonary disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 109 | $81,991 |
| Dupixent PenDupilumab | 15 | $50,917 |
| Roflumilast | 15 | $2,120 |
| Azithromycin | 55 | $875 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $802 |
| Prednisone | 88 | $310 |
| Montelukast Sodium | 12 | $165 |
| Methylprednisolone | 21 | $133 |
| Levofloxacin | 15 | $38 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Morgantown
- Roger AbrahamsMorgantown$133K
- Sidharth BhasinMorgantown$7K
- Andrzej JaworskiMorgantown$5K
- Kyle ChapmanMorgantown$5K
- Haroon AhmedMorgantown$4K
- Mehdi FarishtaMorgantown$4K
- Sarah HadiqueMorgantown$4K
- Srinivasa PotlaMorgantown$3K
- Robert StansburyMorgantown$3K
- Joseph RussoMorgantown$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.